RASA2 and neoplasm: Further, RASA2-deleted CAR T-cells demonstrated improved in vitro functionality and superior early in vivo anti-tumor responses against DMGs compared with controls.<h4>Conclusions</h4>Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells.